<DOC>
	<DOCNO>NCT00572897</DOCNO>
	<brief_summary>Stem cell transplantation use treat may type disease . There 2 type transplant , conventional ( intense ) reduce intensity-non-myeloablative , also call mini-transplants . This study propose use condition regimen allogeneic transplantation along reduced intensity transplant . Conditioning regiment name combination chemotherapy drug give patient receive transplantation donor stem cell . It hop regimen design study prof less toxic equal good anticancer effect regimens normally use . The regimen use combination two chemotherapy drug , fludarabine melphalan . This regimen study recipient match sibling transplant recipient alternative donor stem cell hematologic malignancy . Those subject , receive stem cell unrelated donor , also receive additional drug call ATG anti thymocyte globulin . ATG suppress immune system , thus reduce chance recipient reject transplant ( graft ) . The purpose study observe reduce intensity transplant use allow engraftment `` take '' donor 's bone marrow . Studies conduct past show type transplant much less toxic traditional bone marrow transplant . Reduced intensity transplant may well tolerate patient may experience serious side effect standard ( intense ) stem cell transplant . The study recently amend follow subject survival .</brief_summary>
	<brief_title>Study Fludarabine Based Conditioning Allogeneic Stem Cell Transplantation Myelofibrosis</brief_title>
	<detailed_description>This study design single arm Phase II clinical trial patient myelofibrosis eligible transplantation relate donor unrelated donor source . Patients accrue two separate stratum define donor type . Each two stratum analyze separately . Patients follow yearly time enrollment study assess clinical response overall , progression event free survival , well incidence degree acute chronic GVHD . We estimate cumulative survival transplant related mortality patient enrol two stratum .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients follow disease : Idiopathic myelofibrosis , spend PV , ETrelated myelofibrosis chronic phase ( &lt; 20 % blast cell bone marrow ) Lille score &gt; 1 time , platelet &lt; 100K . Age 1865 year . ECOG performance status &lt; 3 . Life expectancy &gt; 3 month . Adequate cardiac function , normal LVEF ≥ 45 % MUGA echocardiogram adequate pulmonary function DLCO ≥ 50 % predict . Serum creatinine &lt; 1.1 x upper limit normal ( ULN ) Creatinine Clearance &gt; 50 ml/min . Serum bilirubin &lt; 2.0 mg/dl , SGPT &lt; 2.5 x upper limit normal No evidence chronic active hepatitis cirrhosis HIVnegative Patient pregnant Patient guardian able sign inform consent . Patients &gt; 20 % myeloblast blood marrow , extramedullary blast cell proliferation large focus blast bone marrow biopsy specimen eligible . Pretransplant splenectomy : MMM patient variable degree splenomegaly , splenectomized , eligible enrol . Any decision patient splenectomized prior transplant make center prior enrol patient study . Patients treatment investigational least 4 week recovered toxicity . Pregnancy HIV positive &gt; 20 % myeloblast peripheral blood bone marrow LVEF &lt; 45 % DLCO &lt; 50 % predict ECOG performance status ≥ 3 Chronic active hepatitis cirrhosis Chronic renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Myeloproliferative disease</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Allogeneic Transplant</keyword>
	<keyword>Conditioning Regimen</keyword>
	<keyword>Reduced Intensity Regimen</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Melphalan</keyword>
	<keyword>ATG</keyword>
</DOC>